Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.76 |
| ▸ | EGFR | P00533 | 5/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | JAK1 | P23458 | 2/20 | 0.60 |
| ▸ | TTK | P33981 | 1/20 | 0.60 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209826 | 0.86 | JAK3 (1.00) | JAK3EGFRJAK2JAK1FGFR4 | |
| SCHEMBL17209928 | 0.84 | JAK3 (0.66) | JAK3EGFRJAK2JAK1TTK | |
| SCHEMBL23152743 | 0.81 | EGFR (0.70) | JAK3EGFRJAK2JAK1TTK | |
| SCHEMBL14812608 | 0.79 | JAK3 (0.78) | JAK3EGFRJAK2JAK1TTK | |
| SCHEMBL14812381 | 0.78 | JAK3 (0.77) | JAK3EGFRJAK2JAK1TTK | |
| SCHEMBL23152840 | 0.78 | EGFR (0.63) | JAK3EGFRJAK2JAK1TTK | |
| SCHEMBL17209937 | 0.77 | JAK3 (0.84) | JAK3EGFRJAK2JAK1FGFR4 | |
| SCHEMBL15808061 | 0.77 | EGFR (0.69) | EGFRFGFR4 | |
| SCHEMBL28887510 | 0.77 | JAK3 (0.58) | JAK3EGFRJAK2JAK1TTK | |
| SCHEMBL15827828 | 0.76 | EGFR (1.00) | JAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164614-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK3, JAK1, JAK2 | JAK3 1/4885EGFR 692/4885JAK2 3/4885 |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | JAK3, JAK1, JAK2 | JAK3 1/4885EGFR 692/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.